

Do not  
enter. JN  
2/2/04

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of claims:**

Claims 1-10: (canceled)

Claim 11. (currently amended): ~~The method according to claim 10,~~ A method of identifying evidence of a neoplasm in a biological sample comprising:

(a) examining a level of expression of 20P1F12/TMPRSS2 gene, which encodes the protein of SEQ. ID. NO: 2 (Figure 1), in a test biological sample; and

(b) comparing the level of said 20P1F12/TMPRSS2 gene expression in the test biological sample to a level of said 20P1F12/TMPRSS2 gene expression found in a comparable normal biological sample,

wherein an enhanced level of said 20P1F12/TMPRSS2 gene products in the test biological sample relative to the normal biological sample is evidence of a neoplasm, and

wherein the neoplasm is a prostate cancer.

Claim 12-18: (canceled)

Claim 19. (currently amended): ~~The method of claim 18,~~ A method of identifying evidence of a neoplasm in a biological sample comprising:

(a) examining a level of expression of 20P1F12/TMPRSS2 gene, which encodes the protein of SEQ. ID. NO: 2 (Figure 1), in a test biological sample; and

(b) comparing the level of said 20P1F12/TMPRSS2 gene expression in the test biological sample to a level of said 20P1F12/TMPRSS2 gene expression found in a comparable normal biological sample,

wherein an enhanced level of said 20P1F12/TMPRSS2 gene products in the test biological sample relative to the normal biological sample is evidence of a neoplasm,

wherein the 20P1F12/TMPRSS2 evaluated in the test biological sample is secreted from neoplastic cells, and wherein the neoplastic cells are prostate cancer cells.